

Mississippi Division Of Medicaid
Provider Notice of Preferred Drug List Changes
P&T Meeting Date: May 9, 2023
PDL Changes Effective Date: July 1, 2023



The following changes will be made to the Preferred Drug List (PDL), effective July 1, 2023, pending approval by the P&T Committee, DOM, and DOM's Executive Director.

NEW PREFERRED DRUGS	
THERAPEUTIC CLASS	RECOMMENDED for PREFERRED STATUS
ANTICONVULSANTS	tiagabine
ANTIEMETICS	aprepitant
ANTINEOPLASTICS	everolimus
ANTIOBESITY SELECT AGENTS	CONTRACE (naltrexone/bupropion)
ANTIOBESITY SELECT AGENTS	SAXENDA (liraglutide)
ANTIOBESITY SELECT AGENTS	WEGOVY (semaglutide)
ANTIPSYCHOTICS	asenapine maleate
ANTIRETROVIRAL	lopinavir/ritonavir
BRONCHODIALATORS, BETA AGONISTS	albuterol HFA
MULTIPLE SCLEROSIS	fingolimod
MULTIPLE SCLEROSIS	teriflunomide
OPHTHALMIC ANTIBIOTICS	tobramycin/dexamethasone suspension

NEW NON-PREFERRED DRUGS	
THERAPEUTIC CLASS	RECOMMENDED for NON-PREFERRED STATUS
ANALGESIC/ANESTHETICS	VOLTAREN GEL (diclofenac)
ANTIBIOTICS& RELATED, GI	REBYOTA (fecal microbiota)
ANTIBIOTICS, VAGINAL	XACIATO GEL (clindamycin)
ANTICONVULSANTS	GABITRIL (tiagabine)
ANTIEMETICS	EMEND (aprepitant)
ANTINEOPLASTICS	JAYPIRCA (pirtobrutinib)

Mississippi Division Of Medicaid
Provider Notice of Preferred Drug List Changes
P&T Meeting Date: May 9, 2023
PDL Changes Effective Date: July 1, 2023



NEW NON-PREFERRED DRUGS	
THERAPEUTIC CLASS	RECOMMENDED for NON-PREFERRED STATUS
ANTINEOPLASTICS	LYTGOBI (futibatinib)
ANTINEOPLASTICS	KRAZATI (adagrasib)
ANTINEOPLASTICS	REZLIDHIA (olutasidenib)
ANTINEOPLASTICS	AFINITOR (everolimus)
ANTINEOPLASTICS	ZORTRESS (everolimus)
ANTIOBESITY SELECT AGENTS	orlistat
ANTIOBESITY SELECT AGENTS	XENICAL (orlistat)
ANTIPSYCHOTICS	SAPHRIS (asenapine maleate)
ANTIRETROVIRAL	SUNLENCA (lenacapavir)
ANTIRETROVIRAL	KALETRA (lopinavir/ritonavir)
COLONY STIMULATING FACTOR	ROLVEDON (eflapegfilgrastim)
COLONY STIMULATING FACTOR	STIMUFEND (pegfilgrastim)
CYTOKINE & CAM ANTAGONISTS	AMJEVITA (adalimumab)
MULTIPLE SCLEROSIS	AUBAGIO (teriflunomide)
MULTIPLE SCLEROSIS	BRIUMVI (ublituximab)
MULTIPLE SCLEROSIS	TASCENSO ODT (fingolimod)
OPHTHALMIC ALLERGIC CONJUNCTIVITIS	VERKAZIA (cyclosporine)
OPHTHALMIC ANTIBIOTICS	TOBRADEX suspension (tobramycin/dexamethasone)
STIMULANTS & RELATED AGENTS	XELSTRYM (dextroamphetamine)